Kimberly Fox

Cell therapy is built on a simple but powerful idea: harnessing the potential of living cells to help fight disease. ​Researchers continue exploring new ways to engineer and apply cells, expanding our understanding of how these approaches may help treat certain cancers. ​ At Legend Biotech, we're advancing research across multiple cell therapy platforms. Learn more: bit.ly/3WWsThd #CellTherapy #Oncology

Access matters. Our treatment center network has grown to over 150 activated treatment centers, further strengthening our nationwide footprint. Every new treatment center represents another step toward expanding access to CAR-T cell therapy for patients in more communities. At Legend Biotech, we're committed to advancing innovation while helping connect more patients to these therapies. #PatientsFirst #CellTherapy #CART #LegendBiotech

What is CAR-T cell therapy? This personalized approach uses a patient’s own T cells to help fight cancer. Learn how it works and why continued innovation matters for people living with blood cancers. #CellTherapy #PatientsFirst #Oncology #Biotech

Innovation starts with impact. 12,000+ patients have been treated with our CAR-T therapy developed by Legend Biotech and our partners. That experience informs our progress as we advance next-gen cell therapies, including in vivo CAR-T approaches highlighted by new LB2501 data.

At @EHA_Hematology 2026, Legend Biotech shared new LB2501 data and joined the global hematology community in conversations around unmet patient needs. We’re proud to support research helping shape the future of cell therapy. #EHA2026 #CellTherapy #Hematology

#LegendNews: At @EHA_Hematology, we presented Phase 1 data for LB2501, our investigational in vivo CD19/CD20 dual-targeting CAR-T therapy. Results showed clinical activity after a single infusion and a favorable safety profile to date. Read more: bit.ly/4erUIIR

#LegendNews at #EHA2026. We’ll present initial Phase 1 LB2501 data in relapsed/refractory B-cell NHL in a late-breaking oral presentation. The abstract highlights encouraging clinical activity and a favorable safety profile. Learn more: bit.ly/4o6cjKS @EHA_Hematology

We asked a few of our leaders what they’re most excited about heading into the weekend. Their response wasn’t a single study or session. Instead, it highlighted the momentum across the oncology community. #ASCO26

The energy at #ASCO26 feels different this year. More conversations around earlier intervention. More momentum behind cell therapy. More urgency around what comes next. A few reflections from the Legend team onsite today.

#LegendNews: Early LB2102 data in solid tumors will be presented at #ASCO26. Additional data presented at @ASCO reinforce established efficacy and safety profile in #MultipleMyeloma. Come find us at ASCO Booth #21955 to learn more and read more at: bit.ly/4f16QCG

At @ASCO, we'll present new data across our cell therapy portfolio, including investigational LB2102 findings in solid tumors and our CAR-T program in multiple myeloma. We remain focused on advancing cell therapy innovation and oncology research. #ASCO26 #CellTherapy

#LegendNews: Legend has engaged leading scientific advisors to help guide the advancement of our pipeline and next-generation cell therapy innovation. Their expertise across oncology, immunology & translational science will help shape our R&D strategy. 🔗investors.legendbiotech.com/…